NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) had its price target reduced by from $10.00 to $8.00 in a research note published on Wednesday. They currently have a buy rating on the biopharmaceutical company’s stock.

NBY has been the topic of several other reports. Zacks Investment Research raised NovaBay Pharmaceuticals from a hold rating to a buy rating and set a $5.00 price target on the stock in a research note on Thursday, September 21st. HC Wainwright set a $6.00 price target on NovaBay Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 11th. ValuEngine lowered NovaBay Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, November 10th. Maxim Group restated a hold rating on shares of NovaBay Pharmaceuticals in a report on Friday, August 11th. Finally, Roth Capital set a $5.00 price objective on NovaBay Pharmaceuticals and gave the company a buy rating in a report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has an average rating of Hold and an average price target of $6.33.

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) opened at $4.60 on Wednesday. NovaBay Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $5.00.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.09). NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%. The business had revenue of $4.09 million during the quarter, compared to analyst estimates of $4.69 million.

ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Analyst Recommendations for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.